Results 121 to 130 of about 4,942 (259)

Retrospective Evaluation of LDL-C Levels Following First Treatment With Inclisiran as Part of Secondary Prevention ASCVD Risk Reduction in a Real-World Primary Care Setting

Journal of Primary Care & Community Health
Introduction: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability worldwide. There is a direct relationship between increasing levels of LDL-C and increased risk of ASCVD.
Carl N. Deaney, Meredith P. Donaldson, Danielle M. Reesby, Victoria L. Scott, Victoria Ellis, Georgia E. Cole, Natalie M. C. Daly, Sophie C. McKechnie, Michelle Daff, Sarah L. Knudsen, Charles H. Hemingway-Deaney, Alena Nicholson, Laura Siauciuniene, Azeem Azeez, Agne Meskauskiene   +14 more
doaj   +1 more source

Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular risk [PDF]

, 2021
Gaetano Santulli, Stanislovas S. Jankauskas, Jessica Gambardella   +2 more
openalex   +1 more source

Pregnancy 3 months after inclisiran injection: a unique case report including newborn baby monitoring

European Heart Journal: Case Reports
Background Data on the safety of inclisiran, a lipid-lowering small interfering RNA (siRNA) inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) secretion, during pregnancy are absent.
M. Allevi, Matteo Landolfo, F. Giulietti, F. Spannella, Riccardo Sarzani   +4 more
semanticscholar   +1 more source

Idiosyncratic Drug-Induced Liver Injury in a Healthy Patient following PCSK9-Inhibitor Injection

Case Reports in Hepatology
Background. Acute liver injury is a life-threatening condition with disparate aetiology. Swift and adequate interdisciplinary treatment is essential to assure the best possible outcomes in these patients.
B.-O. Stüben, D. P. Hoyer, S. Radunz, F. Saner, H. Schmidt, H. A. Baba, J. W. Treckmann, L. I. Mazilescu   +7 more
doaj   +1 more source

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia

Diseases, 2018
The discovery of proprotein convertase subtilisin-kexin type 9 (PCSK9), a serine protease which binds to the low-density lipoprotein (LDL) receptors and targets the receptors for lysosomal degradation, offered an additional route through which plasma LDL-
Constantine E. Kosmas, Alba Muñoz Estrella, Andreas Sourlas, Delia Silverio, Elizabeth Hilario, Peter D. Montan, Eliscer Guzman   +6 more
doaj   +1 more source

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

, 2022
Kausik K. Ray, Frederick J. Raal, David Kallend, Mark Jaros, Wolfgang Köenig, Lawrence A. Leiter, Ulf Landmesser, Gregory G. Schwartz, David Lawrence, Andrew Friedman, Lorena Garcia Conde, R. Scott Wright, ORION Phase III investigators   +12 more
openalex   +1 more source

Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis

BMC Cardiovascular Disorders
Objective Hyperlipidemia plays a crucial role in increasing the risk of cardiovascular diseases such as atherosclerosis. Recent studies have established that inclisiran positively influences lipid regulation. Nevertheless, its effectiveness in comparison
Shengxuan Zhang, Lei Sun, Xinyu Xu, Yanling Zhang, Qilan Chen   +4 more
doaj   +1 more source

Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease

Vascular Health and Risk Management, 2023
Michael S Albosta,1 Jelani K Grant,2 Pam Taub,3 Roger S Blumenthal,2 Seth S Martin,2 Erin D Michos2 1Internal Medicine Department, University of Miami Miller School of Medicine/ Jackson Memorial Hospital, Miami, FL, USA; 2Ciccarone Center for the ...
Albosta MS, Grant JK, Taub P, Blumenthal RS, Martin SS, Michos ED   +5 more
doaj  

Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials [PDF]

, 2021
Wolfgang Köenig, Kausik K. Ray, D G Kallend, Ulf Landmesser, L. A. Leiter, Gregory G. Schwartz, R. Scott Wright, Lorena Garcia Conde, M Jaros, Frederick J. Raal   +9 more
openalex   +1 more source

Inclisiran Sodium

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources